Informações:
Falhas:
ID
34421
Descrição
ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT01360554
Link
https://clinicaltrials.gov/show/NCT01360554
Palavras-chave
Versões (1)
- 17/01/2019 17/01/2019 -
Titular dos direitos
see on clinicaltrials.gov
Transferido a
17 de janeiro de 2019
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Similar models
Eligibility Non-Small Cell Lung Cancer (NSCLC) NCT01360554
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
ID.1
Item
evidence of pathologically confirmed, advanced nsclc (with known histology).
boolean
ID.2
Item
prior treatment with at least one and no more than two systemic therapy regimens (at least one must be standard chemotherapy for advanced nsclc).
boolean
ID.3
Item
adequate tissue sample must be submitted prior to randomization for tumor biomarker analyses.
boolean
ID.4
Item
adequate renal, hematologic, liver function.
boolean
ID.5
Item
ecog ps of 0-2.
boolean
ID.6
Item
radiologically measurable disease.
boolean
ID.7
Item
small cell histology.
boolean
ID.8
Item
symptomatic brain mets or known leptomeningeal mets.
boolean
ID.9
Item
prior therapy with agent known or proposed to be active by action on egfr tyrosine kinase or other her family proteins.
boolean
ID.10
Item
uncontrolled medical disorders.
boolean